(VIANEWS) – Amphastar Pharmaceuticals (AMPH), Novo Nordisk A/S (NVO), United Therapeutics Corporation (UTHR) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Amphastar Pharmaceuticals (AMPH)
34% sales growth and 24.59% return on equity
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Earnings Per Share
As for profitability, Amphastar Pharmaceuticals has a trailing twelve months EPS of $2.56.
PE Ratio
Amphastar Pharmaceuticals has a trailing twelve months price to earnings ratio of 21.41. Meaning, the purchaser of the share is investing $21.41 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.59%.
Moving Average
Amphastar Pharmaceuticals’s worth is under its 50-day moving average of $55.96 and higher than its 200-day moving average of $50.43.
Yearly Top and Bottom Value
Amphastar Pharmaceuticals’s stock is valued at $54.82 at 15:22 EST, way below its 52-week high of $67.66 and way higher than its 52-week low of $27.99.
Revenue Growth
Year-on-year quarterly revenue growth grew by 50.3%, now sitting on 601.31M for the twelve trailing months.
Sales Growth
Amphastar Pharmaceuticals’s sales growth is 30.8% for the current quarter and 34% for the next.
Previous days news about Amphastar Pharmaceuticals(AMPH)
- According to Zacks on Friday, 26 January, "Chicago, IL - January 26, 2024 - Today, Zacks Equity Research discusses Amphastar Pharmaceuticals (AMPH Quick QuoteAMPH – Free Report) , Teva Pharmaceutical (TEVA Quick QuoteTEVA – Free Report) and Dr. Reddy’s Laboratories (RDY Quick QuoteRDY – Free Report) ."
2. Novo Nordisk A/S (NVO)
24.6% sales growth and 88.77% return on equity
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Earnings Per Share
As for profitability, Novo Nordisk A/S has a trailing twelve months EPS of $2.44.
PE Ratio
Novo Nordisk A/S has a trailing twelve months price to earnings ratio of 44.25. Meaning, the purchaser of the share is investing $44.25 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 88.77%.
3. United Therapeutics Corporation (UTHR)
18.7% sales growth and 17.52% return on equity
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhance the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing OreniPro, RemoPro, Tyvaso DPI, Trevyent, Ralinepag, and Aurora-GT to treat PAH; Unexisome to treat bronchopulmonary dysplasia; and the research and development of various organ transplantation-related technologies, including regenerative medicine, xenotransplantation, and ex-vivo lung perfusion, as well as the development of medicine for other diseases. It has licensing and collaboration agreements with Medtronic, Inc. to develop and commercialize the implantable system for Remodulin; Caremark, L.L.C. to provide refills of implanted pumps at its infusion centers; DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of Remodulin; MannKind Corporation to develop and license treprostinil inhalation powder and Dreamboat devices; and Arena Pharmaceuticals, Inc. to develop ralinepag for the treatment of PAH. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Earnings Per Share
As for profitability, United Therapeutics Corporation has a trailing twelve months EPS of $18.12.
PE Ratio
United Therapeutics Corporation has a trailing twelve months price to earnings ratio of 12.09. Meaning, the purchaser of the share is investing $12.09 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.52%.
4. Stantec (STN)
13.8% sales growth and 14.18% return on equity
Stantec Inc. provides e professional services in the areas of infrastructure and facilities to the public and private sectors clients in Canada, the United States, and internationally. The company provides consulting services in engineering, architecture, interior design, landscape architecture, surveying, environmental sciences, project management, and project economics. It also offers planning and design consulting services to clients in residential, logistics, retail, infrastructure, energy, higher education, and urban regeneration sectors; architectural and interior design, and planning services in the science and technology, commercial workplace, higher education, residential, and hospitality markets. In addition, it provides transportation planning and engineering services; project delivery consultancy services for mining, resources, and industrial infrastructure projects; and paleontological and archaeological services for the rail, transportation, water, and power and energy sectors. Further, the company offers environmental and cultural resource compliance services, as well as serves science and technology, commercial workplace, higher education, residential, and hospitality markets. Additionally, it is involved in the design, development, and delivery of sustainable projects; and design, construction administration, commissioning, maintenance, decommissioning, and remediation activities. The company was formerly known as Stanley Technology Group Inc. and changed its name to Stantec Inc. in October 1998. Stantec Inc. was founded in 1954 and is headquartered in Edmonton, Canada.
Earnings Per Share
As for profitability, Stantec has a trailing twelve months EPS of $2.2.
PE Ratio
Stantec has a trailing twelve months price to earnings ratio of 36.8. Meaning, the purchaser of the share is investing $36.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.18%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Stantec’s EBITDA is 37.89.
Revenue Growth
Year-on-year quarterly revenue growth grew by 13.5%, now sitting on 4.95B for the twelve trailing months.
5. Verisk Analytics (VRSK)
10.2% sales growth and 66.78% return on equity
Verisk Analytics, Inc. provides data analytics solutions to the insurance markets in the United States and internationally. The company provides predictive analytics and decision support solutions to customers in rating, underwriting, claims, catastrophe and weather risk, global risk analytics, and various other fields. It focuses on the prediction of loss, selection and pricing of risk, and compliance with their reporting requirements for property and casualty insurance customers, as well as develops machine learned and artificially intelligent models to forecast scenarios and produce standard and customized analytics that help its customers to manage their businesses, including detecting fraud before and after a loss event, and quantifying losses. The company was founded in 1971 and is headquartered in Jersey City, New Jersey.
Earnings Per Share
As for profitability, Verisk Analytics has a trailing twelve months EPS of $5.33.
PE Ratio
Verisk Analytics has a trailing twelve months price to earnings ratio of 45.8. Meaning, the purchaser of the share is investing $45.8 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 66.78%.
Moving Average
Verisk Analytics’s value is higher than its 50-day moving average of $237.43 and above its 200-day moving average of $228.31.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Verisk Analytics’s EBITDA is 106.74.
Yearly Top and Bottom Value
Verisk Analytics’s stock is valued at $244.12 at 15:22 EST, below its 52-week high of $249.26 and way higher than its 52-week low of $169.74.
Sales Growth
Verisk Analytics’s sales growth is 6.5% for the present quarter and 10.2% for the next.
6. Hartford Financial Services Group (HIG)
9.9% sales growth and 17.43% return on equity
The Hartford Financial Services Group, Inc. provides insurance and financial services to individual and business customers in the United States, the United Kingdom, and internationally. Its Commercial Lines segment offers insurance coverages, including workers' compensation, property, automobile, general and professional liability, package business, umbrella, fidelity and surety, marine, livestock, and reinsurance through regional offices, branches, sales and policyholder service centers, independent retail agents and brokers, wholesale agents, and reinsurance brokers. The company's Personal Lines segment provides automobile, homeowners, and personal umbrella coverages through direct-to-consumer channel and independent agents. Its Property & Casualty Other Operations segment offers coverage for asbestos and environmental exposures. The company's Group Benefits segment provides group life, disability, and other group coverages to members of employer groups, associations, and affinity groups through direct insurance policies; reinsurance to other insurance companies; employer paid and voluntary product coverages; disability underwriting, administration, and claims processing to self-funded employer plans; and a single-company leave management solution. This segment distributes its group insurance products and services through brokers, consultants, third-party administrators, trade associations, and private exchanges. Its Hartford Funds segment offers managed mutual funds across various asset classes; and exchange-traded products through broker-dealer organizations, independent financial advisers, defined contribution plans, financial consultants, bank trust groups, and registered investment advisers, as well as investment management, distribution, and administrative services, such as product design, implementation, and oversight. The company was founded in 1810 and is headquartered in Hartford, Connecticut.
Earnings Per Share
As for profitability, Hartford Financial Services Group has a trailing twelve months EPS of $7.27.
PE Ratio
Hartford Financial Services Group has a trailing twelve months price to earnings ratio of 11.95. Meaning, the purchaser of the share is investing $11.95 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.43%.
Dividend Yield
As maintained by Morningstar, Inc., the next dividend payment is on Nov 29, 2023, the estimated forward annual dividend rate is 1.88 and the estimated forward annual dividend yield is 2.21%.
Volume
Today’s last reported volume for Hartford Financial Services Group is 774075 which is 50.96% below its average volume of 1578490.
